2nd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$980,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.

LobbyistCovered position, as disclosed
HANNAH BETH CORNWELL —
ERIN MENDELSOHN —
KRISTIN RICHTER —
MATTHEW O SCHUMAKER —
SWARNA VALLURUPALLI —

Contacted: White House Office; Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3832 (118th), H.R. 7142 (118th), S. 1375 (118th), H.R. 830 (118th), H.R. 7085 (118th)

Medicare/Medicaid MMM

General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.

LobbyistCovered position, as disclosed
HANNAH BETH CORNWELL —
ERIN MENDELSOHN —
KRISTIN RICHTER —
MATTHEW O SCHUMAKER —
SWARNA VALLURUPALLI —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.